Cytokinetics CYTK

$61.23 -1.10 (-1.76%)

Valuation

Market cap
7,755,909,000
Revenue TTM
$88,040,000
Net income TTM
$-784,960,000
PE ratio
0.00
Forward PE
—
Profit margin
-891.59%
Debt to equity
-1.59

Trading

Volume
985,600
Avg volume
1,935,628
Day's range
$60.89 – $62.44
Shares out
124,433,000
Stochastic %K
7%
Beta
0.41
Analysts
Strong Sell
Price target
$107.14

Price

Company profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule...

Show more

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 624 3000
Website
https://www.cytokinetics.com
Address
350 Oyster Point Boulevard, South San Francisco, United States

Latest news

Stocktwits

buddyopalosam Oct 23, 12:27 PM
$CYTK this is trading like the expansion will not get approved.
0 replies
Merlintrader Oct 22, 9:00 PM
$CYTK Latest company news, Oct 21, 2026: Cytokinetics will report Q3 results on November 4, with a call at 4:30 p.m. ET, ten days before the November 14 FDA date. Cytokinetics ($CYTK): What Is the November 14 PDUFA Date Actually For? https://www.merlintrader.com/cytokinetics-incorporated-stock-hub/ Chart (daily): price around 62.3, below the 50-day (about 69.2) and 200-day (about 70.1) moving averages, with the 50-day now turning below the 200-day. The falling trendline from the July high near 88 is now around 67, while the 60 area has held as support since early October. Not investment advice.
0 replies
BiotechSwings Oct 22, 8:56 PM
Nov 14 is 23 days out and $CYTK is acting like it is still next quarter MAPLE HCM sNDA decision, aficamten as a single drug beat metoprolol on peak VO2, up 1.1 vs down 1.2 in Phase 3 MYQORZO is already approved in obstructive HCM, so this is a label widening, not a first approval gamble closed 62.33 today, down 0.84 percent off 62.86. quiet drift into a dated catalyst is kind of my favorite setup ngl
0 replies
Quantumup Oct 22, 10:26 AM
Baird🏁 $KARD and said -- Initiating coverage with an Outperform rating and $43 price target. $CYTK EWTX BMY TNYA $MLYS AZN RCKT ALNY RHHBY TECX TENX MRK BAYRY IONS Baird added—We like Kardigan's three-asset precision-cardiology portfolio, anchored by danicamtiv's potential to improve heart function in familial/genetic DCM, where we believe the myosin activator mechanism is well-positioned for success (particularly in the sarcomeric core patients). In addition to danicamtiv, ataciguat in CAVS and tonlamarsen in ASH offer additional higher-risk higher-reward shots-on-goal and with Phase 2 readouts across all three programs expected 1H27, we see multiple opportunities for clinical validation (all three of which target high-unmet-need indications) to drive share-price appreciation.
0 replies
BiotechSwings Oct 19, 9:55 PM
26 days out on $CYTK and the calendar keeps stacking in its favor Nov 14 PDUFA on the MAPLE HCM sNDA. aficamten as monotherapy beat metoprolol on peak VO2 in Phase 3, up 1.1 vs down 1.2 Canada just became the fifth approval for MYQORZO today. US, China, Europe and the UK already in. ngl the label conversation into Nov 14 is not starting from zero
0 replies
Merlintrader Oct 19, 4:52 PM
Latest company news, October 19, 2026: Health Canada authorized MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (NYHA class II-III) in adults, according to Cytokinetics. Cytokinetics ($CYTK) Stock Hub: November 14 PDUFA, MYQORZO Deeper dive in our hub. Not investment advice.
0 replies
Quantumup Oct 16, 5:13 PM
William Blair🏁 $KARD and said -- We are initiating coverage of Kardigan with an Outperform rating, and our DCF-based valuation is $38 per share. $CYTK BMY EWTX $MLYS AZN TNYA RCKT ALNY TECX TENX Here's what William Blair went on to say in its initiation report: https://x.com/Quantumup1/status/2111143177692295554?s=20
0 replies
Quantumup Oct 16, 10:22 AM
William Blair🏁 $EWTX and said -- We are initiating coverage of Edgewise with an Outperform rating; our DCF-adjusted valuation is $53 per share. $CYTK $BMY TECX AZN NVO BAYRY MLYS TENX Here's what William Blair had to say: https://x.com/Quantumup1/status/2111039712416637267?s=20
0 replies